Asarfi Hospital
add_icon

Asarfi Hospital

195.00
-3.00
(-1.52%)
Market Cap
₹383.70 Cr
PE Ratio
28.65
Volume
10,000.00
Day High - Low
₹196.00 - ₹191.00
52W High-Low
₹221.00 - ₹72.90
hide
Key Fundamentals
Add Ratio
split_icon_default
Market Cap
383.70 Cr
EPS
5.37
PB Ratio
4.41
Book Value
44.87
EBITDA
31.10
Dividend Yield
0.00 %
Sector
Hospitals
ROE Growth %
-
Debt to Equity
0.53
Forecast For
Actual

Company News

View All News
Caret
positive
Asarfi Hospital Limited reported strong quarterly results with revenue reaching ₹80.6 crore (50% YoY growth) and PAT growing 70% to ₹7.32 crore, driven by doubled inpatient volumes and successful Cancer Institute launch. The company outlined Vision 2027 targets of 500 beds capacity, ₹200 crore revenue, and 25-27% EBITDA margin through expansion into Bihar and Eastern Uttar Pradesh, advanced service lines including bone marrow transplants, and vertical integration with education services.
positive
Asarfi Hospital Limited achieved consolidated revenue of Rs 80.6 crores in H1 FY26, marking 50% year-on-year growth, with PAT rising 70% to Rs 7.32 crores and EBITDA growing 38% to Rs 15.86 crores. The company operates two hospitals in Dhanbad with 330 beds combined and projects Rs 160 crores revenue for FY26 and Rs 200 crores for FY27, while planning expansion to 500 beds by 2027.
positive
Asarfi Hospital Limited announced its unaudited standalone and consolidated financial results for the half-year ended September 30, 2025. The company's Board of Directors approved the results at a meeting held on November 10, 2025. The statutory auditors issued an unmodified opinion on the financial statements. During the quarter, the company secured a term loan of ₹4.68 crore from State Bank of India for purchasing and installing a new Cath Lab at Asarfi Hospital, Dhanbad, along with a ₹2.00 crore fund-based Bank Guarantee limit for various empanelments with corporates and PSUs. The company operates in the hospital segment and has a subsidiary named Asarfi Educational Foundation.
View more
Competitors
LTP
Market Cap (₹ Cr.)
P/E Ratio
Revenue (₹ Cr.)
YoY Revenue Growth %
Net Profit (₹ Cr.)
YoY Profit Growth %
RSI
1,087.90
#1 1,05,769.60
77.19
7,184.10
#1 28.65
1,076
#1 74.34
39.59
7,009.50
1,00,785.86
58.38
#1 21,994.30
14.76
#1 1,505
24.84
23.08
855.85
64,613.09
62.04
7,849.70
13.25
809
70.27
25.72
1,884.90
38,519.97
#1 44.91
5,575.00
12.29
790
30.03
48.82
616.40
31,936.98
89.52
4,286.70
15.12
337
14.65
31.34
1,143.00
30,722.74
55.41
3,771.40
12.59
481
21.10
31.09
658.20
26,337.14
74.59
3,067.00
21.98
415
-40.35
35.66
506.50
16,013.42
106.79
1,757.00
27.64
110
71.36
49.55
1,379.70
14,012.12
54.26
1,566.90
17.46
244
-4.30
59.83
705.00
9,940.51
243.37
2,257.70
17.03
49
0.00
42.74
Growth Rate
Revenue Growth
48.78 %
Net Income Growth
152.38 %
Cash Flow Change
-116.69 %
ROE
120.98 %
ROCE
83.68 %
EBITDA Margin (Avg.)
17.71 %

Quarterly Financial Results

Quarterly Financials
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Mar 2025
Jun 2025
Sept 2025
Revenue
21
24
24
32
34
39
37
46
Expenses
16
20
18
24
26
29
29
36
EBITDA
5
4
5
8
8
10
8
10
Operating Profit %
20 %
16 %
21 %
22 %
21 %
15 %
20 %
20 %
Depreciation
3
4
3
3
3
3
3
3
Interest
1
1
1
1
1
1
1
1
Profit Before Tax
1
-1
2
4
4
5
4
6
Tax
1
-1
0
1
1
2
1
2
Net Profit
-0
-0
2
3
3
4
3
4
EPS in ₹
-0.03
-0.18
0.74
1.45
1.36
1.82
1.59
2.13

Balance Sheet

Balance Sheet
2024
2025
Total Assets
154
164
Fixed Assets
94
102
Current Assets
46
59
Capital Work in Progress
0
2
Investments
0
0
Other Assets
60
60
Total Liabilities
154
164
Current Liabilities
44
41
Non Current Liabilities
39
42
Total Equity
70
81
Reserve & Surplus
51
61
Share Capital
20
20

Cash Flow

Cash Flow
2024
2025
Net Cash Flow
-1
1
Investing Activities
-63
-7
Operating Activities
26
-4
Financing Activities
36
13

Share Holding

% Holding
Mar 2023
Jul 2023
Sept 2023
Mar 2024
Sept 2024
Mar 2025
Jun 2025
Sept 2025
Promoter
83.03 %
61.17 %
61.17 %
61.17 %
61.17 %
61.17 %
61.17 %
61.17 %
FIIs
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.10 %
0.05 %
DIIs
0.00 %
0.37 %
3.25 %
2.33 %
1.95 %
2.92 %
3.18 %
2.19 %
Government
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
Public / Retail
0.00 %
23.73 %
27.40 %
31.63 %
32.99 %
30.86 %
29.89 %
30.89 %
Others
16.97 %
14.74 %
8.18 %
4.87 %
3.89 %
5.05 %
5.66 %
5.70 %
No of Share Holders
37
1,248
706
1,261
1,284
1,262
1,176
1,167

Corporate Action

Record Date Corporate Action Information Announcement Day LTP at Annoucement LTP at Record Day
30 Jan 2024 EXTRAORDINARY GENERAL MEETING Extraordinary General Meeting
NA
30 Jan 2024 83.07 94.14
13 Sept 2024 ANNUAL GENERAL MEETING Annual General Meeting
NA
13 Sept 2024 62.88 63.15
30 Oct 2024 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
30 Oct 2024 59.99 63.60
31 Jan 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
31 Jan 2025 93.67 94.88
08 May 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
08 May 2025 89.81 94.41
07 Aug 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
07 Aug 2025 131.05 128.25
12 Sept 2025 ANNUAL GENERAL MEETING Annual General Meeting
NA
12 Sept 2025 126.50 147.00
10 Nov 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
10 Nov 2025 143.00 143.00

Announcements

Update Of Group Meeting Of Analyst/Institutional Investor Meetings Held On December 4 20256 days ago
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation8 days ago
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationNov 27, 2025
Announcement under Regulation 30 (LODR)-Earnings Call TranscriptNov 22, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeNov 19, 2025
Intimation Of Material Event - Grant Of AccreditationNov 17, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationNov 15, 2025
Submission Of Standalone & Consolidated Unaudited Financial Results For The Half Year Ended September 30 2025Nov 12, 2025
Announcement under Regulation 30 (LODR)-Investor PresentationNov 10, 2025
Submission Of Standalone & Consolidated Unaudited Financial Results For The Quarter And Half Year Ended September 30 2025Nov 10, 2025
Board Meeting Outcome for Outcome Of The Board Meeting Held On November 10 2025 And Submission Of Standalone & Consolidated Unaudited Financial Results For The Quarter And Half Year Ended September 302025Nov 10, 2025
Intimation Regarding Credit Rating - Asarfi Hospital Limited.Oct 13, 2025
Closure of Trading WindowOct 11, 2025
Board Meeting Outcome for Intimation Of Appointment Of Cost AuditorSep 25, 2025
Disclosure Regarding Clerical Error In Debtors Ageing Statement In The Financial Statements For The Year Ended March 31 2025Sep 20, 2025
Shareholder Meeting / Postal Ballot-Scrutinizers ReportSep 13, 2025
Shareholder Meeting / Postal Ballot-Outcome of AGMSep 12, 2025
Reg. 34 (1) Annual Report.Aug 21, 2025
Board Meeting Outcome for Outcome Of Board Meeting Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) 2015.Aug 20, 2025
Board Meeting Intimation for Intimation Of Board Meeting For Consideration And Approval Of BoardS Report And Notice Of AGM.Aug 12, 2025
Financial Result For Quarter Ended 30Th June2025Aug 07, 2025
Announcement under Regulation 30 (LODR)-Investor PresentationAug 07, 2025
Board Meeting Outcome for Outcome Of Board Meeting Held On 07Th August 2025 And Submission Of Unaudited Financial Results For The Quarter Ended 30Th June 2025.Aug 07, 2025
Board Meeting Outcome for Reply To Discrepancy - Reason For Delay In Intimation Of Appointment Of Company Secretary And Compliance OfficerAug 06, 2025
Board Meeting Intimation for Consider And Approve The Unaudited Financial Results Of The Company For The Quarter Ended 30Th June2025.Jul 31, 2025
Closure of Trading WindowJun 27, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJun 06, 2025
Appointment of Company Secretary and Compliance OfficerJun 04, 2025
Board Meeting Outcome for Intimation Under Regulation 30 Of SEBI (LODR) Regulations 2015 - Appointment Of Compliance Officer Cum Company Secretary.Jun 04, 2025
Integrated Filing (Financial)May 24, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseMay 19, 2025
Announcement under Regulation 30 (LODR)-Earnings Call TranscriptMay 14, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeMay 12, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMay 09, 2025
Announcement under Regulation 30 (LODR)-Investor PresentationMay 09, 2025
Board Meeting Outcome for Outcome Of Board Meeting Held On 08Th May 2025 And Submission Of Standalone & Consolidated Audited Financial Results For The Quarter Ended & Year Ended 31St March 2025 As Per SEBI (Listing Obligations And Disclosure Requirements)May 08, 2025
Board Meeting Intimation for Intimation Under Regulation 29(1)(A) Of SEBI Listing Regulations 2015.May 02, 2025
Closure of Trading WindowMar 29, 2025
Board Meeting Outcome for Outcome Of Board Meeting Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Mar 28, 2025
Intimation Of Material Event-High Court Jharkhand Order Civil Litigation Related To Cancer Hospital Land.Mar 13, 2025
Announcement under Regulation 30 (LODR)-Resignation of Company Secretary / Compliance OfficerMar 03, 2025
Announcement under Regulation 30 (LODR)-Investor PresentationJan 31, 2025
Outcome Of Board Meeting Held On 31St January 2025 And Submission Of Unaudited Financial Results For The Quarter Ended 31St December 2024 As Per SEBI (Listing Obligations And Disclosure Requirements) Jan 31, 2025
Board Meeting Intimation for Intimation Under Regulation 29(1)(A) Of SEBI Listing Regulations 2015 To Consider And Approve The Unaudited Financial Results For The Quater Ended 31St Dec2025.Jan 23, 2025
Announcement under Regulation 30 (LODR)-Earnings Call TranscriptNov 09, 2024
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeNov 06, 2024
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationNov 01, 2024
Intimation Of Material Event - Possession & Registry Of Land.Nov 01, 2024
Announcement under Regulation 30 (LODR)-Investor PresentationOct 30, 2024
Outcome Of Board Meeting Held On 30Th October, 2024 And Submission Of Unaudited Financial Results For The Half Year Ended 30Th September, 2024 As Per SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015.Oct 30, 2024

Technical Indicators

RSI(14)
Neutral
59.64
ATR(14)
Less Volatile
9.97
STOCH(9,6)
Neutral
56.33
STOCH RSI(14)
Oversold
9.79
MACD(12,26)
Bearish
-2.12
ADX(14)
Strong Trend
26.20
UO(9)
Bearish
66.31
ROC(12)
Downtrend And Accelerating
-4.69
WillR(14)
Neutral
-45.36